GOALS OF WORK: The goal of this study is to characterize sleep quality and quantity prior to and in the first three nights after initial chemotherapy for breast cancer. MATERIALS AND METHODS: This study makes use of secondary analysis of data from two separate randomized clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. Participants were women with stage I-IIIA breast cancer treated with anthracycline and/or cyclophosphamide-based regimens. MAIN RESULTS: Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first night's sleep was the worst. There was no statistically significant relationship between self-reported poor sleep and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI >5) had significantly lower (p < 0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. Increasing age was also associated with poorer sleep. CONCLUSIONS: A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. Interventions should focus on strategies to decrease the number and duration of night awakenings. Further research is needed to identify predictors of poor sleep during this time.
RCT Entities:
GOALS OF WORK: The goal of this study is to characterize sleep quality and quantity prior to and in the first three nights after initial chemotherapy for breast cancer. MATERIALS AND METHODS: This study makes use of secondary analysis of data from two separate randomized clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. Participants were women with stage I-IIIA breast cancer treated with anthracycline and/or cyclophosphamide-based regimens. MAIN RESULTS: Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first night's sleep was the worst. There was no statistically significant relationship between self-reported poor sleep and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI >5) had significantly lower (p < 0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. Increasing age was also associated with poorer sleep. CONCLUSIONS: A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. Interventions should focus on strategies to decrease the number and duration of night awakenings. Further research is needed to identify predictors of poor sleep during this time.
Authors: Susan L Beck; Anna L Schwartz; Gail Towsley; William Dudley; Andrea Barsevick Journal: J Pain Symptom Manage Date: 2004-02 Impact factor: 3.612
Authors: Sonia Ancoli-Israel; Roger Cole; Cathy Alessi; Mark Chambers; William Moorcroft; Charles P Pollak Journal: Sleep Date: 2003-05-01 Impact factor: 5.849
Authors: Barry V Fortner; Edward J Stepanski; Stephanie C Wang; Sarah Kasprowicz; H Heith Durrence Journal: J Pain Symptom Manage Date: 2002-11 Impact factor: 3.612
Authors: Maria Tejada; Carol Viele; Kord M Kober; Bruce A Cooper; Steven M Paul; Laura B Dunn; Marilyn J Hammer; Fay Wright; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Sleep Date: 2019-10-09 Impact factor: 5.849
Authors: Alejandro Chaoul; Kathrin Milbury; Amy Spelman; Karen Basen-Engquist; Martica H Hall; Qi Wei; Ya-Chen Tina Shih; Banu Arun; Vicente Valero; George H Perkins; Gildy V Babiera; Tenzin Wangyal; Rosalinda Engle; Carol A Harrison; Yisheng Li; Lorenzo Cohen Journal: Cancer Date: 2017-09-20 Impact factor: 6.860
Authors: Joseph A Roscoe; Michael L Perlis; Wilfred R Pigeon; Kristen H O'Neill; Charles E Heckler; Sara E Matteson-Rusby; Oxana G Palesh; Michelle Shayne; Alissa Huston Journal: J Psychosom Res Date: 2011-09-22 Impact factor: 3.006
Authors: Christina Van Onselen; Bruce A Cooper; Kathryn Lee; Laura Dunn; Bradley E Aouizerat; Claudia West; Marylin Dodd; Steven Paul; Christine Miaskowski Journal: Support Care Cancer Date: 2012-10 Impact factor: 3.603
Authors: Kristin Garrett; Anand Dhruva; Theresa Koetters; Claudia West; Steven M Paul; Laura B Dunn; Bradley E Aouizerat; Bruce A Cooper; Marylin Dodd; Kathryn Lee; William Wara; Patrick Swift; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2011-03-31 Impact factor: 3.612